Clinical Study
Induction Chemotherapy in Technically Unresectable Locally Advanced Carcinoma of Maxillary Sinus
Table 3
Selected results in carcinoma maxillary sinus.
| | Study | Number | Proportion of T4 | Local control | OS |
| | Paulino et al. [5] | 48 | 50% | Sx + RT 3 years—65.2%
RT 3 years—22.7% | NR | | Jansen et al.* [6] | 73 | 59% | Sx + RT 5 years—65.0%
RT 5 years—47% | Sx+RT 5 years—60.0%
RT 5 years—9% | |
Waldron et al. [15] | 110 | 71% | Five years—42% | Cause specific survival (5 years)—43% | |
Hayashi et al. [7] | 62 | 48% | CT-RT + Sx 5 years—84%
RT 5 years—18.2% | CT-RT + Sx 5 years—68.5%
RT 5 years—9.1% | |
Myers*et al. [16] | 141 | 88% | 51% median 336 days | Five years disease specific survival—52% | | Duthoy* et al. [17] | 39 | 44% | Two years—73%
Cribriform plate invasion: 7 months | Two years—68%
| | Dirix et al. [18] | 127 | | Five years: 53% | Five years 54% | | Hoppe et al. [20] | 85 | 52% | Five years local progression free: 62% | Five years overall survival: 67% | | Gabriele* et al. [12] | 31 | | Sx + RT 5 years—74.0%
RT 5 years—20% | Sx + RT 5 years—72.0%
RT 5 years—25% | | Hoppe et al. [20] | 39 | 39 | Five years: 21% | Five years: 15% | | Ramalingam et al. [22] | 24 | 12 | Five years: 25% | Five years: 25% | | Qureshi et al. [9] | 73 | 36 | Three years: 54.8% | Three years: 38% | | Jang et al. [4] | 30 | 22 | Five years: 29% | Five years: 34% |
|
|
These studies which have included paranasal sinus patients rest are restricted to maxillary sinus carcinomas.
|
